"Galactosylceramides" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Cerebrosides which contain as their polar head group a galactose moiety bound in glycosidic linkage to the hydroxyl group of ceramide. Their accumulation in tissue, due to a defect in beta-galactosidase, is the cause of galactosylceramide lipidosis or globoid cell leukodystrophy.
| Descriptor ID |
D005699
|
| MeSH Number(s) |
D02.065.313.250.450 D09.400.410.420.525.200.250.450 D10.390.470.675.200.250.450 D10.570.877.360.612.200.250.450
|
| Concept/Terms |
Galactosylceramides- Galactosylceramides
- Galactosyl Ceramides
- Ceramides, Galactosyl
- Galactocerebrosides
|
Below are MeSH descriptors whose meaning is more general than "Galactosylceramides".
Below are MeSH descriptors whose meaning is more specific than "Galactosylceramides".
This graph shows the total number of publications written about "Galactosylceramides" by people in this website by year, and whether "Galactosylceramides" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1999 | 0 | 1 | 1 |
| 2001 | 1 | 0 | 1 |
| 2002 | 0 | 1 | 1 |
| 2003 | 1 | 0 | 1 |
| 2006 | 1 | 0 | 1 |
| 2009 | 2 | 0 | 2 |
| 2011 | 1 | 0 | 1 |
| 2012 | 0 | 1 | 1 |
| 2014 | 0 | 1 | 1 |
| 2017 | 1 | 1 | 2 |
| 2018 | 1 | 1 | 2 |
| 2019 | 0 | 1 | 1 |
| 2021 | 1 | 1 | 2 |
To return to the timeline,
click here.
Below are the most recent publications written about "Galactosylceramides" by people in Profiles.
-
Reduced dose of PTCy followed by adjuvant a-galactosylceramide enhances GVL effect without sacrificing GVHD suppression. Sci Rep. 2021 06 23; 11(1):13125.
-
Donor Treg expansion by liposomal a-galactosylceramide modulates Tfh cells and prevents sclerodermatous chronic graft-versus-host disease. Immun Inflamm Dis. 2021 09; 9(3):721-733.
-
CD160 serves as a negative regulator of NKT cells in acute hepatic injury. Nat Commun. 2019 07 22; 10(1):3258.
-
4"-O-Alkylated a-Galactosylceramide Analogues as iNKT-Cell Antigens: Synthetic, Biological, and Structural Studies. ChemMedChem. 2019 01 08; 14(1):147-168.
-
IL-21 Selectively Protects CD62L+ NKT Cells and Enhances Their Effector Functions for Adoptive Immunotherapy. J Immunol. 2018 10 01; 201(7):2141-2153.
-
Leptin receptor antagonism of iNKT cell function: a novel strategy to combat multiple myeloma. Leukemia. 2017 12; 31(12):2678-2685.
-
Synthesis of C6''-modified a-C-GalCer analogues as mouse and human iNKT cell agonists. Org Biomol Chem. 2017 Mar 08; 15(10):2217-2225.
-
Colocalization of a CD1d-Binding Glycolipid with a Radiation-Attenuated Sporozoite Vaccine in Lymph Node-Resident Dendritic Cells for a Robust Adjuvant Effect. J Immunol. 2015 Sep 15; 195(6):2710-21.
-
Improving Mycobacterium bovis bacillus Calmette-Gu?rin as a vaccine delivery vector for viral antigens by incorporation of glycolipid activators of NKT cells. PLoS One. 2014; 9(9):e108383.
-
Sublingual vaccination induces mucosal and systemic adaptive immunity for protection against lung tumor challenge. PLoS One. 2014; 9(3):e90001.